Detalhe da pesquisa
1.
Induction-concurrent chemoradiotherapy with or without sintilimab in patients with locoregionally advanced nasopharyngeal carcinoma in China (CONTINUUM): a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial.
Lancet
; 403(10445): 2720-2731, 2024 Jun 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-38824941
2.
Elective upper-neck versus whole-neck irradiation of the uninvolved neck in patients with nasopharyngeal carcinoma: an open-label, non-inferiority, multicentre, randomised phase 3 trial.
Lancet Oncol
; 23(4): 479-490, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35240053
3.
Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma.
N Engl J Med
; 381(12): 1124-1135, 2019 09 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-31150573
4.
Primary tumor regression speed after radiotherapy and its prognostic significance in nasopharyngeal carcinoma: a retrospective study.
BMC Cancer
; 14: 136, 2014 Feb 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-24571531
5.
Reduced-Volume Irradiation of Uninvolved Neck in Patients With Nasopharyngeal Cancer: Updated Results From an Open-Label, Noninferiority, Multicenter, Randomized Phase III Trial.
J Clin Oncol
; 42(17): 2021-2025, 2024 Jun 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-38507662
6.
Medial retropharyngeal nodal region sparing radiotherapy versus standard radiotherapy in patients with nasopharyngeal carcinoma: open label, non-inferiority, multicentre, randomised, phase 3 trial.
BMJ
; 380: e072133, 2023 02 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36746459
7.
Final Overall Survival Analysis of Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma: A Multicenter, Randomized Phase III Trial.
J Clin Oncol
; 40(22): 2420-2425, 2022 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35709465